Welcome to our dedicated page for Tecogen SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Tecogen Inc. (TGEN) SEC filings, giving investors a primary source of regulatory information about the company’s operations, financial condition, and capital markets activity. Tecogen is a Delaware corporation with common stock listed on the NYSE American, and it files periodic and current reports with the U.S. Securities and Exchange Commission under this listing.
Through its registration statement on Form S-1 and subsequent filings, Tecogen describes its business as designing, manufacturing, marketing, selling, installing, and maintaining high-efficiency, ultra-clean cogeneration products, including natural gas engine-driven combined heat and power systems, air conditioning systems, and high-efficiency water heaters. Filings also explain its three reportable segments: Products, Services, and Energy Production, which together cover equipment sales, long-term service contracts, and energy sales in the form of electricity, heat, hot water, and cooling.
Key filing types for Tecogen include:
10-K and 10-Q: Annual and quarterly reports that present audited or reviewed financial statements, segment disclosures, risk factors, and management’s discussion of results across Products, Services, and Energy Production. These documents also discuss factors such as demand fluctuations, competing technologies, regulatory changes, incentives and rebates, and financing conditions.
8-K: Current reports used by Tecogen to announce material events, such as quarterly earnings releases and supplemental presentations, underwritten public offerings of common stock, executive appointments, debt prepayments, and Regulation FD disclosures about investor FAQs and presentations on topics like AI data center chillers and hybrid drive technology.
S-1 and related offering documents: Registration statements and prospectuses that describe Tecogen’s capital raises, including the terms of public offerings, use of proceeds for product development, sales and marketing, additional human resources, capital expenditures, and anticipated expansion into the data center market.
On Stock Titan, AI-powered tools can help interpret lengthy Tecogen filings by summarizing complex sections, highlighting segment trends, and surfacing disclosures about items such as non-GAAP measures (for example, Adjusted EBITDA) and risk factors. Users can quickly locate information on TGEN’s reporting segments, capital structure, and material events, while real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, S-1, and other filings are captured as they become available.
On 21 Jul 2025, Tecogen Inc. (TGEN) filed an 8-K announcing the closing of a firm-commitment underwritten public offering of 3,985,000 common shares (incl. 485,000 overallotment) at $5.00 per share. Gross proceeds equal roughly $19.9 million; after underwriting discounts and estimated expenses, net proceeds are about $18.16 million.
Roth Capital Partners served as sole manager and underwriter. Management intends to allocate the cash to product development, expanded sales & marketing, additional staffing, capital expenditures, and working capital as the company pursues entry into the data-center market. Exhibit 99.1 contains a related press release, furnished but not deemed filed under the Exchange Act.
Stephen Lafaille, VP of Business Development at Tecogen, reported significant insider trading activity through multiple transactions between March and June 2025. The transactions reveal a pattern of option exercises and subsequent stock sales at progressively higher prices.
Key transaction highlights:
- Initial purchase of 400 shares at $2.50 on March 3, 2025
- Exercised and sold multiple tranches of options: - 10,000 shares ($0.71 exercise, sold at ~$4.88) - 15,000 shares ($0.71 exercise, sold at $5.00) - 25,000 shares ($1.10 exercise, sold at ~$5.98) - 10,000 shares ($1.10 exercise, sold at $7.25)
The insider maintains ownership of 400 shares post-transactions. Notable option holdings include remaining rights to purchase 40,000 shares at $0.71 (expires 2030) and 45,000 shares at $1.10 (expires 2032), subject to vesting conditions tied to EBITDA performance metrics.
Tecogen (OTCQX:TGEN) submitted a routine Form 3 – Initial Statement of Beneficial Ownership on 29 Jun 2025 for newly reported insider Stephen Lafaille, VP of Business Development.
The filing shows Mr Lafaille directly holds 400 common shares and three option grants covering an aggregate 108,862 shares:
- 6,362 options @ $3.93, fully vested, expiring 04/29/2026
- 50,000 options @ $0.71, performance-vested on adjusted EBITDA targets, expiring 07/09/2030
- 52,500 options @ $1.10, time-vested 50% per year, expiring 01/21/2032
No purchase, sale, or other material corporate event is disclosed; the document fulfills Section 16(a) reporting requirements and has no immediate operational or financial impact on Tecogen.
SEC Form 3 filing for Tecogen Inc. (TGEN) discloses the initial beneficial ownership of Chief Accounting Officer Roger P. Deschenes as of 04/23/2024. He directly owns 24,998 shares of Tecogen common stock. In addition, Deschenes holds 140,000 stock options across three grants: 50,000 options at an exercise price of $0.78 expiring 09/21/2030, 52,500 options at $1.10 expiring 01/21/2032, and 37,500 options at $0.88 expiring 09/20/2033. The first grant vests in stages tied to Adjusted EBITDA targets (2% of revenue for two consecutive quarters and 3% for four consecutive quarters), while the second grant vests 50% per year. The third grant becomes exercisable on 09/20/2024. All holdings are reported as directly owned. No other transactions or changes were reported.
Form 4 highlight: Tecogen Inc. (TGEN) President & COO Robert A. Panora filed a Form 4 for transactions dated 06/16/2025.
- Shares acquired: 12,723 @ $0.79, 30,000 @ $0.71 and 52,500 @ $1.10 – a total of 95,223 common shares through option exercises.
- Post-transaction holding: Panora now directly owns 165,223 common shares.
- Remaining derivative position: An unvested option for 100,000 shares at $0.71 remains outstanding; it vests only after Tecogen posts 3 % Adjusted EBITDA for four consecutive quarters and expires on 07/09/2030.
- No shares were sold or disposed of in these transactions.
The filing was signed on 06/20/2025 and indicates that Panora continues to serve as Chief Operating Officer and President. No other insiders were included in this filing.